GeneXpert MTB/RIF Testing in the Management of Patients with Active Tuberculosis; A Real Life Experience from Saudi Arabia
| Autor: | Souad M. Al-Ateah, Noura A. El-Khizzi, Ali Albarrak, Kamran Baig, Fahad M. Al-Onazi, Mohammed F. Al-Otaibi, Ali S. Omrani |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pathology
medicine.medical_specialty GeneXpert MTB/RIF Tuberculosis Routine testing business.industry Pcr assay Saudi Arabia medicine.disease Active tuberculosis bacterial infections and mycoses Smear microscopy Infectious Diseases Median time Pulmonary tuberculosis Internal medicine Medicine Pharmacology (medical) Original Article business |
| Zdroj: | Infection & Chemotherapy |
| ISSN: | 2093-2340 |
| Popis: | BACKGROUND GeneXpert MTB/RIF is a real-time PCR assay with established diagnostic performance in pulmonary and extra-pulmonary forms of tuberculosis. The aim of this study was to assess the contribution of GeneXpert MTB/RIF assay to the management of patients with any form of active tuberculosis in a single large tertiary center in Saudi Arabia, with a special focus on the impact on time to start of antituberculous therapy compared with Ziehl-Neelsen (ZN) smears and mycobacterial cultures. MATERIALS AND METHODS Clinical, radiological and laboratory records for all patients who were commenced on antituberculous therapy between March 2011 and February 2013 were retrospectively reviewed. RESULTS A total of 140 patients were included, 38.6% of which had pulmonary tuberculosis. GeneXpert MTB/RIF was requested for only 39.2% of patients and was the only reason for starting antituberculous therapy for only 12.1%. The median time to a positive GeneXpert MTB/RIF result was 0 days (IQR 3) compared with 0 day (IQR 1) for smear microscopy (P > 0.999) and 22 days (IQR 21) for mycobacterial cultures (P < 0.001). No patients discontinued antituberculous therapy because of a negative GeneXpert MTB/RIF result. CONCLUSIONS In a setting wherein physicians are highly experienced in the diagnosis and treatment of tuberculosis, GeneXpert MTB/RIF was remarkably under-utilized and had only a limited impact on decisions related to starting or stopping antituberculous therapy. Cost-effectiveness and clinical utility of routine testing of all smear-negative clinical samples submitted for tuberculosis investigations by GeneXpert MTB/RIF warrant further study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|